HCV
Clinical trials for HCV explained in plain language.
Never miss a new study
Get alerted when new HCV trials appear
Sign up with your email to follow new studies for HCV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Timing is everything: new study aims to prevent hepatitis c in kidney transplants
Disease control Recruiting nowThis study looks at when to start Hepatitis C (HCV) medication for people without HCV who receive a kidney from an HCV-positive donor. One group starts the medicine before transplant and takes it for 2 weeks; the other starts after transplant and takes it for 12 weeks. The goal i…
Matched conditions: HCV
Phase: NA • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Single test could detect HIV, hepatitis, and syphilis in minutes
Diagnosis Recruiting nowThis study evaluates a new point-of-care device called MagIA H3S that can test for HIV, hepatitis B, hepatitis C, and syphilis from a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard la…
Matched conditions: HCV
Sponsor: MagIA Diagnostics • Aim: Diagnosis
Last updated May 15, 2026 11:55 UTC
-
Peer navigators + smartphone app aim to boost HIV/STI testing in rural appalachia
Prevention Recruiting nowThis study combines peer navigation (trained community members who offer guidance) with a mobile health app to help gay, bisexual, and transgender people in rural Appalachia access HIV, STI, and HCV testing and prevention services. About 141 participants will be split into two gr…
Matched conditions: HCV
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Prevention
Last updated May 17, 2026 01:33 UTC
-
Gut check: new study probes how hepatitis drug changes your microbiome
Knowledge-focused Recruiting nowThis study tracks 20 adults with chronic hepatitis delta (a serious liver infection) who are starting a new drug called bulevirtide. Researchers want to see how the drug changes the gut's bacteria and bile acids over 48 weeks, and how those changes relate to inflammation and live…
Matched conditions: HCV
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC